Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.5950
- TODAY'S CHANGE (%)-0.2250 (-5.8901%)
- Bid / Lots3.5900/ 8
- Ask / Lots3.6000/ 13
- Open / Previous Close3.7900 / 3.8200
- Day Range
- 52 Week Range
- Volume1,463,089
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 10067 | 3.8 |
| 09:33 ET | 300 | 3.795 |
| 09:35 ET | 1200 | 3.77 |
| 09:37 ET | 7755 | 3.75 |
| 09:39 ET | 14270 | 3.74 |
| 09:42 ET | 48105 | 3.705 |
| 09:44 ET | 60916 | 3.67 |
| 09:46 ET | 37324 | 3.6299 |
| 09:48 ET | 24236 | 3.64 |
| 09:50 ET | 4712 | 3.66 |
| 09:51 ET | 11311 | 3.645 |
| 09:53 ET | 13554 | 3.63 |
| 09:55 ET | 5347 | 3.63 |
| 09:57 ET | 9394 | 3.655 |
| 10:00 ET | 15404 | 3.665 |
| 10:02 ET | 4652 | 3.66 |
| 10:04 ET | 10237 | 3.67 |
| 10:06 ET | 4906 | 3.68 |
| 10:08 ET | 500 | 3.6731 |
| 10:09 ET | 44667 | 3.65 |
| 10:11 ET | 10782 | 3.67 |
| 10:13 ET | 19378 | 3.655 |
| 10:15 ET | 30029 | 3.655 |
| 10:18 ET | 45111 | 3.653 |
| 10:20 ET | 6762 | 3.635 |
| 10:22 ET | 9000 | 3.625 |
| 10:24 ET | 5538 | 3.625 |
| 10:26 ET | 35586 | 3.665 |
| 10:27 ET | 21059 | 3.665 |
| 10:29 ET | 2600 | 3.66 |
| 10:31 ET | 5191 | 3.655 |
| 10:33 ET | 8821 | 3.64 |
| 10:36 ET | 87942 | 3.65 |
| 10:38 ET | 26306 | 3.65 |
| 10:40 ET | 26251 | 3.645 |
| 10:42 ET | 3216 | 3.6497 |
| 10:44 ET | 8568 | 3.6484 |
| 10:45 ET | 34408 | 3.65 |
| 10:47 ET | 13340 | 3.665 |
| 10:49 ET | 11594 | 3.655 |
| 10:51 ET | 6316 | 3.6499 |
| 10:54 ET | 9910 | 3.625 |
| 10:56 ET | 16980 | 3.605 |
| 10:58 ET | 3978 | 3.605 |
| 11:00 ET | 23609 | 3.605 |
| 11:02 ET | 20590 | 3.595 |
| 11:03 ET | 3917 | 3.6 |
| 11:05 ET | 4643 | 3.585 |
| 11:07 ET | 8401 | 3.6052 |
| 11:09 ET | 3800 | 3.6 |
| 11:12 ET | 1200 | 3.6 |
| 11:14 ET | 518 | 3.595 |
| 11:16 ET | 21295 | 3.6 |
| 11:18 ET | 14413 | 3.615 |
| 11:20 ET | 13550 | 3.605 |
| 11:21 ET | 9677 | 3.605 |
| 11:23 ET | 16736 | 3.6193 |
| 11:25 ET | 20042 | 3.6194 |
| 11:27 ET | 9900 | 3.6299 |
| 11:30 ET | 7351 | 3.64 |
| 11:32 ET | 8507 | 3.625 |
| 11:34 ET | 4643 | 3.645 |
| 11:36 ET | 1000 | 3.64 |
| 11:38 ET | 5968 | 3.63 |
| 11:39 ET | 4279 | 3.62 |
| 11:41 ET | 12383 | 3.61 |
| 11:43 ET | 2500 | 3.6091 |
| 11:45 ET | 2700 | 3.605 |
| 11:48 ET | 2945 | 3.6193 |
| 11:50 ET | 16036 | 3.605 |
| 11:52 ET | 13466 | 3.605 |
| 11:54 ET | 9150 | 3.605 |
| 11:56 ET | 500 | 3.605 |
| 11:57 ET | 1100 | 3.605 |
| 11:59 ET | 974 | 3.605 |
| 12:01 ET | 6636 | 3.605 |
| 12:03 ET | 16285 | 3.605 |
| 12:06 ET | 3775 | 3.6115 |
| 12:08 ET | 2600 | 3.605 |
| 12:10 ET | 1166 | 3.6011 |
| 12:12 ET | 1100 | 3.61 |
| 12:14 ET | 12015 | 3.605 |
| 12:15 ET | 759 | 3.61 |
| 12:17 ET | 1100 | 3.6 |
| 12:19 ET | 1110 | 3.61 |
| 12:21 ET | 2512 | 3.6 |
| 12:24 ET | 2800 | 3.6075 |
| 12:26 ET | 9948 | 3.5809 |
| 12:28 ET | 15616 | 3.595 |
| 12:30 ET | 1909 | 3.595 |
| 12:32 ET | 32618 | 3.595 |
| 12:33 ET | 27939 | 3.595 |
| 12:35 ET | 3000 | 3.595 |
| 12:37 ET | 600 | 3.59 |
| 12:39 ET | 3232 | 3.61 |
| 12:42 ET | 4282 | 3.6049 |
| 12:44 ET | 400 | 3.6 |
| 12:46 ET | 1364 | 3.61 |
| 12:48 ET | 5883 | 3.605 |
| 12:50 ET | 1400 | 3.605 |
| 12:51 ET | 3500 | 3.6 |
| 12:53 ET | 17674 | 3.6 |
| 12:55 ET | 363 | 3.595 |
| 12:57 ET | 1600 | 3.5973 |
| 01:00 ET | 863 | 3.595 |
| 01:02 ET | 200 | 3.59 |
| 01:04 ET | 990 | 3.5977 |
| 01:06 ET | 3000 | 3.5999 |
| 01:08 ET | 800 | 3.595 |
| 01:09 ET | 2196 | 3.59 |
| 01:11 ET | 2776 | 3.595 |
| 01:13 ET | 1477 | 3.6 |
| 01:15 ET | 2027 | 3.595 |
| 01:18 ET | 4622 | 3.595 |
| 01:20 ET | 1592 | 3.59 |
| 01:22 ET | 1926 | 3.585 |
| 01:24 ET | 3513 | 3.585 |
| 01:26 ET | 1090 | 3.585 |
| 01:27 ET | 35789 | 3.575 |
| 01:29 ET | 3375 | 3.575 |
| 01:31 ET | 3393 | 3.565 |
| 01:33 ET | 22703 | 3.56 |
| 01:36 ET | 1230 | 3.565 |
| 01:38 ET | 18170 | 3.58 |
| 01:40 ET | 4348 | 3.595 |
| 01:42 ET | 200 | 3.595 |
| 01:44 ET | 2745 | 3.595 |
| 01:45 ET | 1159 | 3.595 |
Yesterday
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference, from 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Needham, from 12:35PM ET on Tuesday Nov 12, 2024 by Dow Jones
12:35PM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 12, 2024 by Dow JonesMereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 587.7M | -13.6x | --- |
Kezar Life Sciences Inc | 548.7M | -0.6x | --- |
IGM Biosciences Inc | 599.1M | -2.6x | --- |
Perspective Therapeutics Inc | 601.5M | -6.7x | --- |
AnaptysBio Inc | 613.7M | -3.2x | --- |
Olema Pharmaceuticals Inc | 578.4M | -4.4x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Chief Scientific Officer
- John Lewicki
- General Counsel and Business Development, Company Secretary
- Charles Sermon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $587.7M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.26 |
Book Value | $0.36 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | 484.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,918.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
